Kids' transplant policy change
The organization that oversees national transplant policies has approved a one-year change that makes children younger than 12 eligible for priority on adult lung transplant lists, the group announced Monday.
Condition: Transplant Failure Intervention: Other: BLOOD SAMPLE ANALYSIS Sponsors: Assistance Publique Hopitaux De Marseille; Vaincre la Mucoviscidose Not yet recruiting
We presently forget 98% of everything we experience. That will go away in favor of perfect, controllable, configurable memory. Skills and knowledge will become commodities that can be purchased and installed. We will be able to feel exactly as we wish to feel at any given time. How we perceive the world will be mutable and subject to choice. How we think, the very fundamental basis of the mind, will also be mutable and subject to choice. We will merge with our machines, as Kurzweil puts it. The boundary between mind and computing device, between the individual and his or her tools, will blur. Over the course of the ...
Eighty five percent of congenital heart disease patients currently survive to adulthood due primarily to advancements in surgical treatments1. For these survivors with Adult Congenital Heart Disease (ACHD), heart failure (HF) remains the leading cause of death2. Thus, the number of ACHD patients requiring heart transplantation (HT) continues to grow, and with this growth has come improvements in outcomes. In 2009, Lamour et al. demonstrated a 1-year survival of 83% for non-Fontan congenital HT and 71% for patients with Fontan palliation3.
Treatment decisions in dilated cardiomyopathy (DCM) patients with severe heart failure (HF) and short clinical history are challenging because of the difficulty of determining HF stage or prognosis in the acute HF phase. We hypothesized that persistent decreased systemic or increased pulmonary arterial pressure, including in the subclinical phase, may affect the main pulmonary artery diameter (PAD), ascending aortic diameter (AoD), and their ratio (PAD/AoD). The aims of this study were to assess AoD, PAD, and PAD/AoD by non-contrast computed tomography (CT) scans in DCM patients in the acute phase of HF and to examine the ...
Nowadays, a number of heart failure (HF) patients live with left ventricular assist devices (LVADs) implanted either as a destination therapy or as a bridge to heart transplant or to heart transplant candidacy.1,2 In all these cases, LVAD usually remains for a prolonged time after post-surgical stabilization, during which patients ’ daily quality of life must be improved as much as possible. LVADs are usually set at a fixed number of revolutions per minute (rpm), so that LVAD output changes during daily activities are only preload- and afterload-dependent, with limited variability.
Sirolimus (SRL) attenuates cardiac allograft vasculopathy (CAV) progression following heart transplantation (HT) but often results in hyperlipidemia. We investigated the differential effects of SRL- and calcineurin inhibitor (CNI)-based immunosuppression on CAV progression and clinical outcomes in HT recipients.
: Venovenous (VV) extra corporeal membrane oxygenation (ECMO) is the preferred configuration for bridging respiratory failure patients while awaiting lung transplantation (LTx). However, there is no consensus about intraoperative extracorporeal cardiopulmonary support during LTx in these patients.
Aortic regurgitation (AR) developing under continuous flow-left ventricular assist devices (CF-LVAD) affects 25-30% of patients within the first year of implantation and is being increasingly recognized as a cause of recurrence of symptomatic heart failure (HF). The underlying mechanisms are likely multifactorial, including changes in the leaflets of the aortic valve (AV), altered root biomechanics and excessive left ventricular (LV) unloading, together promoting cusps remodeling and commissural fusion.
Registry data suggest that survival in pulmonary arterial hypertension (PAH) patients has improved from a median of 2.5 years from diagnosis to about 7 years in mostly prevalent cohorts,1,2 which is still dismal. There has long been a concern that initiation of therapy in PAH patients is insufficiently aggressive, given such poor survival. Until recently, data on the utility of combination therapy and the use of initial combination therapy in treatment-na ïve patients has been conflicting, uncontrolled, or nonexistent.
Authors: Ikeda S, Sekine A, Baba T, Katano T, Yamakawa H, Oda T, Iwasawa T, Matsumura M, Takemura T, Ogura T Abstract A man in his 40 s with idiopathic interstitial pneumonia underwent cadaveric left single-lung transplantation from a brain-dead donor in October 2014. In October 2015, chest high-resolution computed tomography revealed centrilobular ground-glass opacities (GGOs) predominantly in the transplanted left lung, and subsequently, the shadows progressed to a geographic GGO without crazy paving. Bronchoalveolar lavage fluid analysis revealed an opaque and milky appearance, and cytopathology demonstrated foa...